Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

References

• AaronsonDWThe “black box” warning and allergy drugsJ Allergy Clin Immunol200611740416387582
   PubMed Web of Science ®Google Scholar
• BillichAAschauerHAszódiAPercutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimusInt J Pharm2004269293514698574
   PubMed Web of Science ®Google Scholar
• BreuerKWerfelTKappASafety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitisAm J Clin Dermatol20056657715799678
   PubMed Web of Science ®Google Scholar
• DraelosZNayakAPariserDPharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparisonJ Am Acad Dermatol200553602916198779
   PubMed Web of Science ®Google Scholar
• FinlayAYKhanGKDermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical useClin Exp Dermatol199419210168033378
   PubMed Web of Science ®Google Scholar
• EichenfieldLEBeckLElidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitisJ Allergy Clin Immunol200311111536812743593
   PubMed Web of Science ®Google Scholar
• EichenfieldLFLuckyAWBoguniewiczMSafety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsJ Am Acad Dermatol20024649550411907497
   PubMed Web of Science ®Google Scholar
• HarperJGreenAScottGFirst experience of topical SDZ ASM 981 in children with atopic dermatitisBr J Dermatol2001144781711298537
   PubMed Web of Science ®Google Scholar
• HoetzeneckerWMeingassnerJGEckerRCorticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cellsJ Invest Dermatol20041226738415086553
   PubMed Web of Science ®Google Scholar
• HoVCGuptaAKaufmannRSafety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infantsJ Pediatr2003421556212584537
   PubMed Web of Science ®Google Scholar
• HultschTElidel (pimecrolimus) cream 1% safety update Feb 2005. [online] CS-5: URL: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4089s2_02_02_Novartis%20Core%20Safety%20(CS).pdf
   Google Scholar
• HultschTKappASpergelJImmunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitisDermatology20052111748716088174
   PubMed Web of Science ®Google Scholar
• KappAPappKBinghamAFlare Reduction in Eczema with Elidel (infants) multicenter investigator study group Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drugJ Allergy Clin Immunol20021102778412170269
   PubMed Web of Science ®Google Scholar
• KiebertGSorensenSVRevickiDAtopic dermatitis is associated with a decrement in health-related quality of lifeInt J Dermatol200241151812010340
   PubMed Web of Science ®Google Scholar
• LeungDYBieberTAtopic dermatitisLancet20033611516012531593
   PubMed Web of Science ®Google Scholar
• MarenholzINickelRRuschendorfFFilaggrin loss-of-function mutations predispose to phenotypes involved in the atopic marchJ Allergy Clin Immunol20061188667117030239
   PubMed Web of Science ®Google Scholar
• McKennaSPWhalleyDde ProstYTreatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of lifeJ Eur Acad Dermatol Venereol2006202485416503881
   PubMed Web of Science ®Google Scholar
• MeingassnerJGAschauerHStuetzAPimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skinExp Dermatol200514752716176283
   PubMed Web of Science ®Google Scholar
• MeingassnerJGKowalskyESchwendingerHPimecrolimus does not affect Langerhans cells in murine epidermisBr J Dermatol2003149853714616380
   PubMed Web of Science ®Google Scholar
• MeurerMFartaschMAlbrechtGCASM-DE-01 Study GroupLong-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitisDermatology20042083657215178928
   PubMed Web of Science ®Google Scholar
• PappKAWerfelTFolster-HolstRLong-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year studyJ Am Acad Dermatol200552240615692468
   PubMed Web of Science ®Google Scholar
• StaabDPariserDGottliebABLow systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis - a multicenter, 3-week, open-label studyPediatr Dermatol2005224657116191004
   PubMed Web of Science ®Google Scholar
• StuetzABaumannKGrassbergerMDiscovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimusInt Arch Allergy Immunol200614119921216926539
   PubMed Web of Science ®Google Scholar
• SunderkötterCWeissJMBextermöllerRPost-marketing surveillance on treatment of 5, 665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of lifeJ Dtsch Dermatol Ges20064301616638059
   PubMedGoogle Scholar
• WahnUBosJDGoodfieldMFlare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study GroupEfficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in childrenPediatrics20021101 Pt 1e212093983
   PubMed Web of Science ®Google Scholar
• WormMForschnerKLeeHHFrequency of atopic dermatitis and relevance of food allergy in adults in GermanyActa Derm Venereol20068611912216648913
   PubMed Web of Science ®Google Scholar
• ZuberbierTChongSUGrunowKThe ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophilsJ Allergy Clin Immunol20011082758011496246
   PubMed Web of Science ®Google Scholar
• ZuberbierTOrlowSJPallerASPatient perspectives on the management of atopic dermatitisJ Allergy Clin Immunol20061182263216815160
   PubMed Web of Science ®Google Scholar